Navigation Links
OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
Date:5/30/2009

se technology, licensed from Isis Pharmaceuticals (NASDAQ: ISIS), to effectively target and inhibit production of specific proteins in tumor cells. OncoGenex and Isis partnered in the successful discovery of OGX-011, OGX-427 and OGX-225 and with respect to OGX-011, in its initial development. In 2008, OncoGenex and Isis amended their OGX-011 agreement to provide OncoGenex with sole rights to OGX-011 and sole responsibility for development and related costs and partnering decisions, subject to financial obligations to Isis. OncoGenex is also solely responsible for development and related costs and partnering decisions regarding OGX-427 and OGX-225. Key intellectual property related to OGX-011, OGX-427 and OGX-225 were discovered by the University of British Columbia and the Vancouver Prostate Centre, and were exclusively licensed to OncoGenex.

More information about OncoGenex is available at www.oncogenex.com.

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements concerning the potential survival benefit of OGX-011, anticipated clinical development activities, timing of these activities, the ability of future trials to demonstrate clinical benefit and the potential for regulatory approvals. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements.

The potential risks and uncertainties associated with forward-looking statements include, among
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
2. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
3. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
4. OncoGenex Reports First Quarter Financial Results
5. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
6. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
7. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
8. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
9. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
10. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
11. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/15/2013)... The topics that will be covered ... framework, scrum roles, scrum meetings, scrum artifacts, and scrum ... (8 PDUs) for attending them. , These trainings are ... directors. It is also ideal for those who will ... the software industry or those who want to explore ...
(Date:6/14/2013)... The OpenClinica Global Conference ... this year with Formedix CEO, Mark Wheeldon presenting as ... attendees a deeper insight into the future developments at ... as Formedix to develop innovative solutions. , The conference ... about OpenClinica, hear real-life case studies and discover more ...
(Date:6/14/2013)... EASTON, Mass. , June 14, 2013  Pressure ... announced that it has closed the third and final ... Preferred Stock and Warrants (the "Series J Private Placement").  ... 6 and $156,900 on March 28, 2013), the Company ... Series J Private Placement, slightly over its goal of ...
(Date:6/13/2013)... Eagle Biosciences is proud to ... Calprotectin ELISA assay kit that offers ... (1-2000 µg/g stool). The Calprotectin ELISA assay kit ... human Calprotectin (neutrophil cytoplasmic protein s100A8/A9, MRP 8/14) ... gastrointestinal assay line which already includes Alpha 1 ...
Breaking Biology Technology:Affordable Scrum Trainings in Chicago on July 12th 2013 by Conscires Agile Practices 2Affordable Scrum Trainings in Chicago on July 12th 2013 by Conscires Agile Practices 3Formedix CEO Invited to Speak at OpenClinica Global Conference in Boston 2Formedix CEO Invited to Speak at OpenClinica Global Conference in Boston 3Pressure BioSciences, Inc. Closes Final Tranche of Series J Above Market Private Placement - Total Amount Raised in PIPE Slightly Exceeds $2 Million Goal 2Pressure BioSciences, Inc. Closes Final Tranche of Series J Above Market Private Placement - Total Amount Raised in PIPE Slightly Exceeds $2 Million Goal 3Pressure BioSciences, Inc. Closes Final Tranche of Series J Above Market Private Placement - Total Amount Raised in PIPE Slightly Exceeds $2 Million Goal 4Pressure BioSciences, Inc. Closes Final Tranche of Series J Above Market Private Placement - Total Amount Raised in PIPE Slightly Exceeds $2 Million Goal 5Eagle Biosciences Introduces Highly Sensitive Calprotectin ELISA Assay Kit 2
... requires substantial reform because it too often fails to support ... to new research from the Economic and Social Research Council ... UN, which has designated 2012 the International Year of Sustainable ... Development Mechanism (CDM), under which companies are allocated tradable credits ...
... National Nanotechnology Initiative (NNI) and the Oregon Nanoscience and ... regional, state, and local (RSL) nanotechnology initiatives. ... April 30 Where: Portland, Oregon at the ... OR Who: Leaders of regional, state, and ...
... 2012 The Foundation of UMDNJ, an affiliate of ... biomarkers grant through the Bill & Melinda Gates Foundation,s ... seeks to overcome persistent bottlenecks in creating new tools ... With the grant, Dr. David Alland, ...
Cached Biology Technology:UN emission market needs urgent reform 2Registration now open: 2012 Regional, State, and Local Initiatives in Nanotechnology 2Foundation of UMDNJ Receives Grand Challenges Tuberculosis Biomarkers Grant 2Foundation of UMDNJ Receives Grand Challenges Tuberculosis Biomarkers Grant 3
(Date:6/17/2013)... their food may turn out to be just as important ... of St. Michael,s Hospital. , The study, led by ... association between poor eating habits in kids ages three to ... cholesterol, putting them at risk for cardiovascular disease later in ... Medical Association Journal today. , "We know that ...
(Date:6/17/2013)... , June 17, 2013 As mobile ... need to secure them grows exponentially, and biometric ... report from Heavy Reading Insider ( ... Heavy Reading ( www.heavyreading.com ). ... the market for biometric authentication on smartphones, analyzing ...
(Date:6/17/2013)... MD (June 17, 2013) The AGA Research Foundation ... in the future of gastroenterology with the 2013 AGA-Horizon ... Student Abstract Prizes. , "In its third year, this ... who are embarking on promising careers in basic and ... of the AGA Research Foundation. "We are extremely proud ...
Breaking Biology News(10 mins):Poor eating behaviors may put preschoolers at risk for later health problems 2Biometric Authentication Provides Better Mobile Device Security, Heavy Reading Finds 2Biometric Authentication Provides Better Mobile Device Security, Heavy Reading Finds 3Horizon Pharma Abstract Prizes recognize promising fellows and students 2
... ethanol production has increased dramatically in recent years ... increased. New U.S. government policies require major increases ... a viable cellulosic ethanol industry, expanded grain ethanol ... acres in the near term, with unintended negative ...
... the first pervasive rule of evolution. In ... Academy of Sciences researchers have found evidence which suggests ... Looking back through the last 550 million ... the team investigated the different evolutionary branches of the ...
... Oregon,s Jim Hutchison already holds three patents in the ... in organizations that promote the technology,s potential in materials ... scientist, however, also embraces a strong call for exploring ... be many, and for designing new materials with reduced ...
Cached Biology News:Fueling ethanol production while protecting water quality 2Fueling ethanol production while protecting water quality 3First 'rule' of evolution suggests that life is destined to become more complex 2Think green, UO's Hutchison says, to reduce nanotech hazards 2Think green, UO's Hutchison says, to reduce nanotech hazards 3
...
Human Regulatory T cell Staining Kit #2 (w/ APC Foxp3 PCH101, FITC CD4, PE CD25)...
Goat anti-VAV2 Class: Antibody Product Group: Miscellaneous Antibody...
Rabbit polyclonal to M13 Bacteriophage Coat Proteins ( Abpromise for all tested applications)....
Biology Products: